US Stock Market Move | New antiemetic drug Nereus approved by FDA, Vanda Pharmaceuticals Inc. (VNDA.US) surges over 32%

On Wednesday, the stock price of Vanda Pharmaceuticals Inc. (VNDA.US) soared, rising over 32% to $9.33 as of press time. On the news front, the company announced that its new drug, Nereus, has been approved by the Food and Drug Administration (FDA) in the United States for the prevention of vomiting induced by motion. The company stated that the FDA's approval decision was based on the results of three clinical studies. These studies compared the medication group with the placebo group to evaluate the occurrence of vomiting. Data showed that Nereus had a "significant reduction" in vomiting events and demonstrated "good safety characteristics" in short-term, acute use scenarios. Vanda announced plans to officially launch Nereus in the coming months. The market generally believes that the approval of this drug is likely to bring new commercial growth opportunities for the company and further enrich its product portfolio in the field of central nervous system and related indications.